Eli Lilly and Company (BKK:LLY80)
Thailand · Delayed Price · Currency is THB | Market Cap | 33.05T +56.3% |
| Revenue (ttm) | 2.36T +47.4% |
| Net Income | 824.94B +127.6% |
| EPS | 918.74 +129.1% |
| Shares Out | n/a |
| PE Ratio | 40.06 |
| Forward PE | 30.38 |
| Dividend | 0.01 (0.45%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 6,337,366 |
| Open | 1.870 |
| Previous Close | 1.870 |
| Day's Range | 1.870 - 1.920 |
| 52-Week Range | 1.010 - 2.020 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade
The GLP-1 race "is not fair to call a race anymore," argues Scott Zari when comparing Eli Lilly (LLY) and Novo Nordisk (NVO), calling the former a clear winner. He explains how Eli Lilly pulled ahead ...
Eli Lilly announces new data from Phase 1 AJX-101 study
Eli Lilly (LLY) announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor demonstrated an “encouraging” safety profile and promising clinical activity i...
Eli Lilly announces Phase 3 BRUIN CLL-322 trial met primary endpoint
Eli Lilly (LLY) and Company announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, plus venetoclax and rituximab versus venetocla...
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
INDIANAPOLIS, June 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton t...
The Next Phase Of The Obesity Drug Race
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Phar...
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095...
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Eli Lilly Stock (LLY) Dips on Reports Employers Plan to Drop Weight-Loss Drug Coverage
Most Americans have health insurance through their employer.
MU, GOOGL, LLY & Other Stocks Andrew Arons is Watching This Summer
Andrew Arons discusses summer market equity expectations and stocks he's watching in the current environment. He points to Micron (MU) as one that has much more room to run even after a stellar year-l...
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
Some employers are planning to drop coverage of GLP-1 drugs for weight loss next year as more people take the medications, counteracting some savings from lower prices for Novo Nordisk's Wegovy and El...
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to the space.
Eli Lilly: FDA approves Ebglyss for one maintenance dose every eight weeks
Eli Lilly (LLY) and Company announced that the U.S. FDA approved a regimen of one maintenance dose every eight weeks of a single injection of Ebglyss for subcutaneous use in…
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the start INDIANAPOLIS, June 9, 2026 /PRNewswire/ -- Eli Lilly and Comp...
As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
Tech stocks are pulling back, and healthcare is surging.
Eli Lilly and Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Obesity therapeutics are in early stages, with major investments in diverse, scalable solutions and global expansion. Retatrutide and eloralintide show strong efficacy and tolerability, while Foundayo and oral GLP-1s drive new patient uptake. Frequent business development supports pipeline growth.
Is It Too Late To Buy The Rally In Eli Lilly Stock?
This article was written and reviewed by Doug Nathman and his team at Trefis. For questions, email help@trefis.com.
Eli Lilly price target raised to $1,350 from $1,330 at Jefferies
Jefferies raised the firm’s price target on Eli Lilly (LLY) to $1,350 from $1,330 and keeps a Buy rating on the shares after the company reported full data from retatrutide’s…
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions
LONDON & BOSTON--(BUSINESS WIRE)--Convatec (LSE:CTEC), a leading medical products and technologies company focused on solutions for the management of chronic conditions; The Eli Lilly and Company Foun...
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
Use of GLP-1 drugs early in pregnancy should not cause alarm
Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is not a cause for alarm, a large new data analysis suggests.
Eli Lilly reports detailed results from three Phase 3 trials in ACHIEVE program
Eli Lilly (LLY) announced detailed results from three Phase 3 trials in the ACHIEVE program evaluating Foundayo, a small molecule oral GLP-1 taken without food or water restrictions, in adults…
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg In ACHIEVE-2 and ACHIEVE-5, Foundayo delivered si...
Eli Lilly stock rises as Retatrutide data boosts obesity drug lead
Shares of Eli Lilly LLY climbed about 4% on Monday after the drugmaker unveiled encouraging new clinical data for its next-generation obesity treatment, retatrutide. This has reinforced investor confi...